Paradigm Biopharmaceuticals . Share Price and Company Fundamentals

0.000 (0.000%)
52 week
0.855 - 2.69

Last traded: Last Thursday at 6:10 AM

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield




Market cap


Enterprise value


Company profile

Primary activitiesParadigm Biopharmaceuticals is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, dege
Industry / SectorBiotechnology / Healthcare
Mailing address500 Collins Street Level 15 Melbourne VIC 3000 Australia
Phone / Fax61 3 9629 5566 / 61 3 9629 5466


More: Paradigm Biopharmaceuticals . Dividend history, yield and payout ratio

Dividend yield


Dividend amount


Payout ratio


Paradigm Biopharmaceuticals . paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.PAR dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.

PAR's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Oct 2022, following are the company executives and directors listed on Paradigm Biopharmaceuticals ..

NameTitleAgeTotal Pay
Dr. Donna L. Skerrett M.D., MSChief Medical Officer and Exec. Director641.1M
Mr. Marco PolizziChief Exec. Officer
Mr. Justin CahillChief Financial Officer
Dr. Ravi KrishnanChief Scientific Officer
Mr. Simon WhiteDirector of Investor Relations
Dr. Michael ImperialeGlobal Head of Drug Safety & MPS
Ms. Beverley HuttmannCommercial Head
Ms. Michelle CoffeyGlobal Head of Regulatory Affairs
Dr. Mukesh AhujaGlobal Clinical Head of OA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.Interim Company Sec.

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Paradigm Biopharmaceuticals . is and its enterprise value is .

The PAR's stocks Beta value is 1.43 making it 43% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Paradigm Biopharmaceuticals . (PAR)

Paradigm Biopharmaceuticals . (ASX:PAR) Frequently Asked Questions

1. What is Paradigm Biopharmaceuticals .'s Stock Symbol?

Paradigm Biopharmaceuticals . trades on ASX under the ticker symbol "PAR".

2. What is Paradigm Biopharmaceuticals .'s stock price today?

One share of PAR stock can currently be purchased for approximately $1.26.

3. How can I contact Paradigm Biopharmaceuticals .?

Paradigm Biopharmaceuticals .'s mailing address is 500 Collins Street Level 15 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9629 5566.

4. What is Paradigm Biopharmaceuticals .'s official website?

The official website of Paradigm Biopharmaceuticals . is

5. Which share registry manages Paradigm Biopharmaceuticals .'s stock?

Paradigm Biopharmaceuticals .'s stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.